468 related articles for article (PubMed ID: 30665272)
1. County-level access to opioid use disorder medications in medicare Part D (2010-2015).
Abraham AJ; Adams GB; Bradford AC; Bradford WD
Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Office-Based Buprenorphine Prescribers for Medicare Patients.
Abraham R; Wilkinson E; Jabbarpour Y; Petterson S; Bazemore A
J Am Board Fam Med; 2020; 33(1):9-16. PubMed ID: 31907241
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
[TBL] [Abstract][Full Text] [Related]
4. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
[TBL] [Abstract][Full Text] [Related]
5. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.
Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H
Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421
[TBL] [Abstract][Full Text] [Related]
6. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
[TBL] [Abstract][Full Text] [Related]
7. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.
Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM
J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440
[TBL] [Abstract][Full Text] [Related]
8. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
[TBL] [Abstract][Full Text] [Related]
9. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.
Ghertner R
Drug Alcohol Depend; 2019 Nov; 204():107527. PubMed ID: 31525570
[TBL] [Abstract][Full Text] [Related]
10. Composition of buprenorphine prescribing networks in Medicaid and association with quality of care.
Zhu JM; Charlesworth CJ; Stein BD; Drake C; Polsky D; Korthuis PT; McConnell KJ
J Subst Use Addict Treat; 2024 Aug; 163():209363. PubMed ID: 38641055
[TBL] [Abstract][Full Text] [Related]
11. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders.
Clark B; Kai M; Dix R; White J; Rozenfeld Y; Levy S; Engstrom K
JAMA Netw Open; 2019 Oct; 2(10):e1913818. PubMed ID: 31642929
[TBL] [Abstract][Full Text] [Related]
12. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120
[TBL] [Abstract][Full Text] [Related]
13. Changes In County-Level Access To Medications For Opioid Use Disorder After Medicare Coverage Of Methadone Treatment Began.
Harris SJ; Yarbrough CR; Abraham AJ
Health Aff (Millwood); 2023 Jul; 42(7):991-996. PubMed ID: 37406230
[TBL] [Abstract][Full Text] [Related]
14. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
15. Analysis of psychiatrists' prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States.
Pan K; Silver S; Davis C
Trends Psychiatry Psychother; 2020; 42(1):48-54. PubMed ID: 32321084
[TBL] [Abstract][Full Text] [Related]
16. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
Andrilla CHA; Moore TE; Patterson DG; Larson EH
J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
[TBL] [Abstract][Full Text] [Related]
17. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
Wen H; Hockenberry JM; Pollack HA
JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
[TBL] [Abstract][Full Text] [Related]
18. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians.
Andrilla CHA; Moore TE; Patterson DG
J Rural Health; 2019 Jan; 35(1):113-121. PubMed ID: 30339720
[TBL] [Abstract][Full Text] [Related]
19. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
[TBL] [Abstract][Full Text] [Related]
20. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
